Ritu Salani

1 week ago | onclive.com | Ritu Salani |Kathleen Moore

OpinionVideoJune 20, 2025Author(s):,Panelists discuss how the evolving role of antibody-drug conjugates (ADCs) in treating gynecologic cancers, including ovarian, endometrial, and cervical cancers, offers exciting opportunities for more personalized treatments that could improve progression-free survival and quality of life, while addressing challenges in therapy sequencing, toxicity management, and biomarker-driven approaches.

1 week ago | onclive.com | Ritu Salani |Kathleen Moore

OpinionVideoJune 20, 2025Author(s):,Panelists discuss how early detection and proactive management of ocular toxicities associated with mirvetuximab soravtansine, including regular screening, eye exams, and collaboration with ophthalmologists, are essential for ensuring timely intervention and minimizing long-term complications such as cataracts, particularly as the drug transitions to broader clinical use.

1 week ago | onclive.com | Ritu Salani |Kathleen Moore

OpinionVideoJune 20, 2025Author(s):,Panelists discuss how managing interstitial lung disease (ILD) associated with antibody-drug conjugates (ADCs) such as mirvetuximab soravtansine requires proactive monitoring, including baseline and ongoing chest CT scans, early intervention with steroids, and close collaboration with pulmonologists and radiologists to minimize risks and ensure patient safety during treatment.

2 weeks ago | onclive.com | Ritu Salani |Kathleen Moore

OpinionVideoJune 13, 2025Author(s):,Panelists discuss how the rapid evolution of antibody-drug conjugates (ADCs) in gynecologic cancers, including promising agents such as mirvetuximab soravtansine and toriluzumab, is generating excitement, with a focus on optimizing treatment sequencing and exploring combinations of ADCs to improve outcomes for patients with platinum-resistant ovarian cancer.

2 weeks ago | onclive.com | Ritu Salani |Kathleen Moore

OpinionVideoJune 13, 2025Author(s):,Panelists discuss how mirvetuximab soravtansine (MIRV), an antibody-drug conjugate, has become a vital treatment for platinum-resistant ovarian cancer, highlighting its effectiveness in patients with high folate receptor alpha expression, its well-tolerated profile with manageable toxicities, and the potential for expanding its use into earlier treatment lines and combination therapies.